Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.671 USD | -9.48% | -6.79% | -18.34% |
03-18 | Forte Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
01-05 | Camac Partners Provides Information to Shareholders | CI |
Valuation
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Capitalization 1 | 467.2 | 31.57 | 21 | 29.86 | 24.42 | - | - |
Enterprise Value (EV) 1 | 408.4 | 31.57 | 21 | 29.86 | 24.42 | 24.42 | 24.42 |
P/E ratio | -5.76 x | -1.38 x | -1.25 x | - | - | - | - |
Yield | - | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - | - |
EV / Revenue | - | - | - | - | - | - | - |
EV / EBITDA | - | - | - | - | - | - | - |
EV / FCF | - | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - | - |
Price to Book | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 12,831 | 14,754 | 21,000 | 36,335 | 36,395 | - | - |
Reference price 2 | 36.41 | 2.140 | 1.000 | 0.8217 | 0.6710 | 0.6710 | 0.6710 |
Announcement Date | 21-03-16 | 22-03-31 | 23-03-31 | 24-03-18 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - |
EBIT 1 | - | -46.28 | - | - | - | -29.02 | -34.04 | -36.6 |
Operating Margin | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) | - | -46.49 | - | - | - | - | - | - |
Net income | -4.069 | -46.49 | -21.71 | -13.88 | - | - | - | - |
Net margin | - | - | - | - | - | - | - | - |
EPS | -0.4100 | -6.320 | -1.550 | -0.8000 | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 20-03-25 | 21-03-16 | 22-03-31 | 23-03-31 | 24-03-18 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2022 Q2 | 2022 Q3 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -7.699 | - | - | - | - | - | -6.516 | -6.912 | -7.547 | -8.041 | -8.223 |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) | -7.751 | - | - | - | - | - | - | - | - | - | - |
Net income | -7.751 | -3.035 | - | -8.896 | - | - | - | - | - | - | - |
Net margin | - | - | - | - | - | - | - | - | - | - | - |
EPS | -0.5400 | -0.2100 | - | -0.4200 | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 21-11-08 | 22-08-15 | 22-11-14 | 23-08-14 | 23-11-13 | 24-03-18 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - | - |
Net Cash position | - | 58.8 | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets | - | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - | - |
Capex | - | - | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - | - | - |
Announcement Date | 20-03-25 | 21-03-16 | 22-03-31 | 23-03-31 | 24-03-18 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-18.34% | 24.42M | |
-1.17% | 104B | |
+2.87% | 97.47B | |
+4.31% | 22.25B | |
-14.77% | 21.68B | |
-9.10% | 18.2B | |
-39.98% | 17.02B | |
-13.21% | 16.36B | |
+8.55% | 14.39B | |
+35.75% | 12.37B |
- Stock Market
- Equities
- FBRX Stock
- Financials Forte Biosciences, Inc.